Wed.Dec 20, 2023

article thumbnail

As ALS research booms, one treatment center finds itself in the spotlight

Bio Pharma Dive

The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.

Research 355
article thumbnail

Roche and Novartis’ Xolair set for FDA priority review in food allergies

Pharmaceutical Technology

The FDA accepted the filing based on NIH-funded Phase III trial interim results, with an approval decision expected in Q1 2024

Allergies 244
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Cause of Alzheimer’s May Be Coming From Inside Your Mouth

AuroBlog - Aurous Healthcare Clinical Trials blog

In recent years, a growing number of scientific studies have backed an alarming hypothesis: Alzheimer’s disease isn’t just a disease, it’s an infection. While the exact mechanisms of this infection are something researchers are still trying to isolate, numerous studies suggest the deadly spread of Alzheimer’s goes way beyond what we used to think.

Research 196
article thumbnail

Argenx autoimmune drug study fails in blow to expansion hopes

Bio Pharma Dive

The Dutch biotech’s star product has lost some luster after a second failed Phase 3 trial in two months, this time for a skin condition called pemphigus.

Drugs 164
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Veteran pharmacy professor G P Mohanta gets Acharya PC Ray Gold Medal Award

AuroBlog - Aurous Healthcare Clinical Trials blog

The HoD of the Department of Pharmacy Practice at the CL Baid Mehta College of Pharmacy in Chennai, Prof. Guruprasad Mohanta has been bestowed with the prestigious Acharya P C Ray Gold Medal Award 2023 instituted by the Bengal branch of the Indian Pharmaceutical Association (IPA).

Pharmacy 183
article thumbnail

GSK adds to ADC dealmaking with second Chinese biotech pact

Bio Pharma Dive

The deal with Hansoh Pharma, GSK’s second this year, gives the company an antibody-drug conjugate in testing for solid tumors like lung cancer.

Antibody 148

More Trending

article thumbnail

Grand Rounds December 15, 2023: Diversifying Clinical Trials: A Path Forward (Roxana Mehran, MD, FACC, FAHA, MSCAI, FESC)

Rethinking Clinical Trials

         Speaker Roxana Mehran, MD, FACC, FAHA, MSCAI, FESC Mount Sinai Endowed Professor of Cardiovascular Clinical Research and Outcomes Professor of Medicine (Cardiology), and Population Health Science and Policy Director, Interventional Cardiovascular Research and Clinical Trials Director, Women’s Heart and Vascular Center at Mount Sinai Heart Icahn School of Medicine at Mount Sinai Slides Keywords Cardiovascular Health, Interventional Cardiovascular Research, Diversity, Health Di

article thumbnail

Teva’s Q3 triumph: 7% revenue surge propelled by Austedo and Ajovy

Pharmaceutical Technology

In Teva Pharmaceutical’s third quarter (Q3) 2023 report, the company reported a significant 7% increase in global revenues, bringing its Q3 sales to $3.9bn.

Sales 130
article thumbnail

After Amryt buyout, Chiesi scores with FDA nod for rare skin disease treatment Filsuvez

Fierce Pharma

Seven months after Krystal Biotech became the first company to gain FDA approval to treat the rare, devastating skin disease epidermolysis bullosa (EB), Chiesi Farmaceutici has followed suit. | Seven months after Krystal Biotech became the first company to gain FDA approval to treat the rare, devastating skin disease epidermolysis bullosa (EB), Chiesi Farmaceutici has followed suit.

article thumbnail

Enabling breakthroughs: How AI is transforming oncology

Pharmaceutical Technology

AI is delivering hugely promising results in oncology, from enhancing drug development to improving the detection of early-stage cancers.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

FDA Denies Accelerated Approval for Clene’s ALS Candidate

BioSpace

Clene disclosed Thursday the FDA has determined that biomarker Neurofilament Light Chain reduction in its Phase II programs “were insufficient to support accelerated approval at this time.

125
125
article thumbnail

Gilead and Compugen partner for new immunotherapy programme

Pharmaceutical Technology

Gilead Sciences has signed a licence agreement for Compugen’s pre-clinical antibody programme against IL-18 binding protein for $848m.

Protein 130
article thumbnail

Merck’s Chronic Cough Drug Fails to Secure FDA Approval for Second Time

BioSpace

The regulator’s Complete Response Letter on Wednesday said Merck’s data package for gefapixant “did not meet substantial evidence of effectiveness.” The FDA also rejected the drug in 2022 due to a lack of efficacy evidence.

article thumbnail

COP28 podcast: max 1.5°C temperature rise limit now ‘not possible’

Pharmaceutical Technology

Andrew Griffiths, a director at Planet Mark, tells a GlobalData COP28 podcast about the need to bring back down the 1.5°C overshoot.

130
130
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Calliditas Therapeutics Nabs Full FDA Approval for IgAN Therapy Tarpeyo

BioSpace

The oral formulation of budesonide, marketed as Tarpeyo, is the only FDA-approved therapy that significantly reduces the loss of kidney function in immunoglobulin A nephropathy patients.

article thumbnail

COP28 podcast: max 1.5°C temperature rise limit now ‘not possible’

Pharmaceutical Technology

Andrew Griffiths, a director at Planet Mark, tells a GlobalData COP28 podcast about the need to bring back down the 1.5°C overshoot.

130
130
article thumbnail

BioNTech wins round in CureVac mRNA patent dispute

pharmaphorum

Shares in CureVac have plummeted after a German court ruled that a patent it holds on mRNA-based COVID-19 vaccines was invalid. The validity of the patent is at the heart of patent litigation between CureVac and fellow German biotech BioNTech and its partner Pfizer, claiming infringement by their Comirnaty coronavirus shot.

article thumbnail

FDA accepts Merck’s pneumococcal vaccine BLA for priority review

Pharmaceutical Technology

The US FDA has accepted the new BLA for Merck’s investigational 21-valent pneumococcal conjugate vaccine, V116, for priority review.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

What VCs look for when investing with MPM Capital, Endeavor Venture Fund and Two Bear Capital

BioSpace

How can startup leaders support long-term sustainable growth and investment? BioSpace’s Lori Ellis speaks with venture capital guests Ansbert Gadicke, Martin Gershon and Mike Goguen for their advice and recommendations on how biopharma startups should approach funding.

116
116
article thumbnail

Neurogene concludes merger deal with Neoleukin Therapeutics

Pharmaceutical Technology

Neurogene has concluded its merger deal with Neoleukin Therapeutics to develop genetic therapies for complex neurological ailments.

Genetics 130
article thumbnail

Does Pay for Performance Work? It Depends

BioSpace

A study finds that employees are more likely to view pay for performance positively—and rise to the challenge of performing well—when they view their managers as friendly and good at their jobs.

116
116
article thumbnail

Biogen fend off generics of MS drug Tecfidera in Europe until 2025

Pharmaceutical Technology

The EC has revoked marketing authorisations for Tecfidera generics, granting the drug marketing protection until February 2025.

Drugs 130
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Calliditas wins over FDA for full approval, broader label on kidney disease drug Tarpeyo

Fierce Pharma

Two years after securing an accelerated approval for its primary immunoglobulin A nephropathy (IgAN) therapy Tarpeyo (budesonide), Calliditas Therapeutics has

Drugs 120
article thumbnail

MYK-224 by Bristol-Myers Squibb for Diastolic Heart Failure (HFpEF): Likelihood of Approval

Pharmaceutical Technology

MYK-224 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Diastolic Heart Failure (HFpEF).

article thumbnail

Key Parkinson’s protein could offer new potential targets for treatment

Pharma Times

The findings could lead to new treatments to target the mTOR and ease PD symptoms - News - PharmaTimes

Protein 140
article thumbnail

GLB-001 by GluBio Therapeutics for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Pharmaceutical Technology

GLB-001 is under clinical development by GluBio Therapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Navigating the Future of Pain Management: Ensysce Biosciences’ Innovative Approach

XTalks

The market for pain management is both complex and substantial, driven by a growing patient population and evolving medical needs. Chronic pain affects millions of people worldwide, significantly impacting their quality of life and posing a substantial economic burden on healthcare systems. The global market for pain management is substantial, driven by an aging population, increased prevalence of chronic diseases and a rising number of surgical procedures.

article thumbnail

Admilparant by Bristol-Myers Squibb for Pulmonary Fibrosis: Likelihood of Approval

Pharmaceutical Technology

Admilparant is under clinical development by Bristol-Myers Squibb and currently in Phase III for Pulmonary Fibrosis.

article thumbnail

A World War II-Era Company Reshapes Itself as a Biotech Powerhouse

BioSpace

Now designated as a Tech Hub by the White House, Alabama’s nonprofit Southern Research is winnowing its focus and investing in healthcare solutions.

Research 121
article thumbnail

Bluebird seeks $250m raise as priority voucher gambit falls short  

Pharmaceutical Technology

Bluebird bio will secure up to $250m after a surprise decision from the FDA to hold back a priority review voucher.

130
130
article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.